Compare Broadcom Inc (AVGO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs Incyte Corporation — how do they compare? Broadcom Inc trades at $415.53 (market cap $1.98T), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Broadcom Inc is far larger — about 80.7× Incyte Corporation's market cap, and Broadcom Inc pays a 0.62% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AVGO | INCY | |
|---|---|---|
Market Cap | $1.98T | $24.54B |
Sector | Technology | Health |
52-Week High | $481.57 | $129.93 |
52-Week Low | $289.60 | $81.61 |
Enterprise Value | $2.02T | $20.04B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $414.83, down 1.79% on the day, amid strong fundamentals including a 38.85% net income margin and consistent earnings beats. Technical analysis shows a bullish trend with key support at $412 and resistance at $422. The company reported robust cash flow from operations of $27.54 billion in 2025 and projects AI semiconductor revenue exceeding $100 billion by 2027, per CEO Hock Tan's reaffirmed forecast (The Motley Fool, 2026-08-11).
Outlook remains positive with 86% analyst buy ratings and a $510.21 consensus price target, though high valuation multiples (P/E 69.23) and competitive pressures in AI chips pose risks. The stock's growth is supported by booked AI revenue and strong cash generation, offering upside if execution continues.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
